From: Quantitative implications of the updated EARL 2019 PET–CT performance standards
Cancer type | Reconstruction | MATV | SUVmax | SUVpeak | SUVmean | TLG | Tumor SUVmax/liver SUVmax | Tumor SUVmax/liver SUVmean |
---|---|---|---|---|---|---|---|---|
Lung cancer | EARL_V2 | -22* (-31/-15) | 30* (22/35) | 23* (14/25) | 25* (18/36) | -1 (-5/2) | 18* (12/22) | 29* (23/35) |
EARL_V2F6 | 0 (-6/2) | 3* (1/6) | 5* (4/7) | 3* (2/6) | 2 (-1/4) | N/A | N/A | |
EARL_V2F7 | 9 (1/14) | -3 (-8/0) | 1 (-2/3) | -2 (-7/0) | 4 (-2/8) | 6* (1/9) | -3 (-8/0) | |
Lymphoma | EARL_V2 | -28* (-36/-19) | 35* (22/41) | 24* (17/29) | 37* (23/42) | -3* (-8/1) | 26* (14/30) | 35* (22/41) |
EARL_V2F6 | -7* (-12/-2) | 6* (2/13) | 6* (3/11) | 6* (0/12) | 0 (-4/4) | N/A | N/A | |
EARL_V2F7 | 0 (-5/7) | 0 (-4/4) | 2 (-2/4) | 0 (-4/4) | 0 (-5/5) | 6* (1/8) | 0 (-4/4) | |
Both combined | EARL_V2 | -27* (-33/-18) | 33* (22/40) | 23* (16/28) | 34* (22/40) | -2* (-7/2) | 22* (14/29) | 34* (23/39) |
EARL_V2F6 | -5* (-11/1) | 5* (1/11) | 5* (3/9) | 5* (2/9) | 1 (-3/4) | N/A | N/A | |
EARL_V2F7 | 2 (-4/11) | -1 (-6/4) | 2* (-2/4) | -1 (-5/4) | 2 (-4/7) | 6* (1/9) | -1 (-6/3) |